Abstract 1517
Background
Previous studies have demonstrated an association between type 2 diabetes mellitus (T2DM) and several types of cancers. However, the role of T2DM in pancreatic neuroendocrine tumors (pNETs) has not been systemically studied.
Methods
A retrospective, follow-up cohort analysis including 299 patients with pNETs was performed. The clinicopathologic characteristics between diabetics and nondiabetic were compared. The overall survival (OS) and progression-free survival (PFS) separated by diabetics and nondiabetic status were analyzed. The association between metformin use and survival was assessed to confirm whether metformin has an impact on prognosis of pNETs.
Results
The prevalence of T2DM was 20.7% (n = 62) in the cohort. For both OS and PFS, diabetic status was associated with a dismal outcome in univariate analyses, and the association was not exist when controlled by stage. The proportion of grade 3 tumor, distant metastasis and nerve invasion was higher in pNETs patients with T2DM than that of patients without T2DM. According to the result of logit regression, pNETs patients with T2DM were at high risk of tumor metastasis (OR = 2.81, P = 0.001), nerve invasion (OR = 2.43, P = 0.029) and grade 3 tumor (OR = 4.97, P = 0.010). Multivariate analysis demonstrated that T2DM was not an independent predictor of OS (P = 0.742) and PFS (P = 0.917). In subset analysis, no significant differences were observed for OS and PFS in subgroup according to their metformin usage.
Conclusions
T2DM is associated with pNETs growth and metastasis, and is not an independent risk factor of poor prognosis in patients with pNETs. No significant association is found between metformin use and survival in pNETs patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xianjun Yu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1988 - Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix
Presenter: Semir Vranic
Session: Poster Display session 2
Resources:
Abstract
2672 - Changes in clinico-pathological characteristics of vulvar cancer in Japan: increasing oldest-old, stage-shifting, and decreasing cohort-level survival
Presenter: Shin Nishio
Session: Poster Display session 2
Resources:
Abstract
4306 - Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase 3 INNOVATE-3/ENGOT-ov50 study
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
5136 - Randomized, phase 1b/2 study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer
Presenter: Susana Banerjee
Session: Poster Display session 2
Resources:
Abstract
2296 - An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
Presenter: Jung-Yun Lee
Session: Poster Display session 2
Resources:
Abstract
2732 - A phase 2 study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Presenter: Ana Oaknin
Session: Poster Display session 2
Resources:
Abstract
4404 - ENGOT-EN9/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Presenter: Christian Marth
Session: Poster Display session 2
Resources:
Abstract
4564 - Phase 1/2 trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
4933 - Updated data of Epitopes-HPV02 trial and external validation of efficacy of DCF in prospective Epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients
Presenter: Stefano Kim
Session: Poster Display session 2
Resources:
Abstract
2301 - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)
Presenter: Alexandra Gilbert
Session: Poster Display session 2
Resources:
Abstract